As first announced at the recent European Society for Medical Oncology (ESMO) World Congress on Gastrtointestinal Cancer (Barcelona, Spain, June 27 - July 1, 2012), there appears to be no benefit shown when adding cetuximab to standard adjuvant chemotherapy in patients wirth resected stage III colon cancer. Dr. Julien Taieb and his team of researchers from the Hopital Europeen Georges Pompidou in Paris, while recognizing FOLFOX as the standard adjuvant therapy for this type and stage of colon cancer, had believed that the addition of cetuximab would provided added benefit. However, while the interim analysis may not have provided the level of support that was anticipated, gastrointestinal cancer experts have not yet given up hope. While "large clinical trials are needed to show significant benefits from new adjuvant chemotherapy", the results of this study are still relevant in continuing to seek out the best possible course of treatment.
More information on this study is available by clicking here.
No comments:
Post a Comment